Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages

Overview of attention for article published in Frontiers in endocrinology, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 3 news outlets
policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 55 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Sep 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Dapagliflozin for Chronic Kidney Disease

Cited by Canadian Agency for Drugs and Technologies in Health on 06 Jun 2022

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.